Clinical Trial Update: COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is evaluating bleeding risk between rivaroxaban and apixaban in patients with atrial fibrillation and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Eliquis (apixaban)
• Xarelto (rivaroxaban)

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: Atrial Fibrillation | Phase 4 | Status: RECRUITING